Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid
Jan 09, 2017 13:05 pm UTC| Business
ANN ARBOR, Mich., Jan. 09, 2017 -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for the treatment of patients with...
Microchip’s Online Store Now Includes All Former Atmel Products
Jan 09, 2017 13:03 pm UTC| Business
CHANDLER, Ariz., Jan. 09, 2017 -- Microchip Technology Inc. (NASDAQ:MCHP), a leading provider of microcontroller, mixed-signal, analog and Flash-IP solutions, today announced that all former Atmel products are now...
AMAG Pharmaceuticals Provides Financial and Business Update
Jan 09, 2017 13:02 pm UTC| Business
2016 total revenue increased 45 percent Provides update on Makena® next-generation program Anticipates 2017 GAAP revenue of $620-$670 million, including Makena net sales of $410-$440 million WALTHAM, Mass.,...
Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
Jan 09, 2017 13:02 pm UTC| Business
PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Mark E. Dudley, Ph.D.has joined the company as...
Jan 09, 2017 13:02 pm UTC| Business
PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (NYSE:GSK) (LSE:GSK) has...
Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study
Jan 09, 2017 13:02 pm UTC| Business
LIVONIA, Mich., Jan. 09, 2017 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced expanded utility for gemcabene with compelling preclinical data results demonstrating proof of concept efficacy in a...
Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study
Jan 09, 2017 13:02 pm UTC| Business
LIVONIA, Mich., Jan. 09, 2017 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced expanded utility for gemcabene with compelling preclinical data results demonstrating proof of concept efficacy in a...